Ola Landgren, MD, PhD | Authors

Ola Landgren, MD, PhD, Discusses IFM 2009 and DETERMINATION Trials of RVd and Lenalidomide Maintenance in Myeloma

June 24, 2022

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.